ǂa ǂretrospective chart review (REFLECT)
Alfredo Addeo (Author), Maximilian J Hochmair (Author), Urška Janžič (Author), Elizabeth Dudnik (Author), Andriani Charpidou (Author), Adam Płużański (Author), Tudor Ciuleanu (Author), Ivan Shterev Donev (Author), Judith Elbaz (Author), Jørgen Aarøe (Author), René Ott (Author), Nir Peled (Author)

Abstract

Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.

Keywords

napredovali nedrobnocelinčni karcinom pljuč;podatki iz resničnega življenja;srednja Evropa;advanced non-small cell lung cancer;real-world data;Central Europe;

Data

Language: English
Year of publishing:
Typology: 1.01 - Original Scientific Article
Publisher: Sage
UDC: 616-006
COBISS: 89318403 Link will open in a new window
ISSN: 1758-8359
Views: 286
Downloads: 94
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary keywords: Carcinoma, non-small cell lung;Immunotherapy;Nedrobnocelični karcinom pljuč;Imunoterapija;Europe;Europe, Eastern;Evropa;Vzhodna Evropa;
Source comment: Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Urška Janžič; Opis vira z dne 14. 12. 2021;
Pages: str. 1-11
Issue: ǂVol. ǂ13
Chronology: 2021
DOI: 10.1177/17588359211059874
ID: 13961696
Recommended works:
, ǂa ǂretrospective analysis of patients treated through an access program
, ǂa ǂretrospective analysis from an early access program
, ǂa ǂ Central European Cooperative Oncology Group analysis